The Hypoxia-Inducible Factor 2 α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor, consisting of an alpha subunit and a beta subunit, that controls cellular responses to hypoxia. HIFalpha contains two transcriptional activation domains called the N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD). HIFalpha is destabilized by prolyl hydroxylation catalyzed by EglN family members. In addition, CTAD function is inhibited by asparagine hydroxylation catalyzed by FIH1. Both hydroxylation reactions are linked to oxygen availability. The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIFalpha for destruction. Recent studies suggest that HIF2alpha plays an especially important role in promoting tumor formation by pVHL-defective renal carcinoma cells among the three HIFalpha paralogs. Here we dissected the relative contribution of the two HIF2alpha transactivation domains to hypoxic gene activation and renal carcinogenesis and investigated the regulation of the HIF2alpha CTAD by FIH1. We found that the HIF2alpha NTAD is capable of activating both artificial and naturally occurring HIF-responsive promoters in the absence of the CTAD. Moreover, we found that the HIF2alpha CTAD, in contrast to the HIF1alpha CTAD, is relatively resistant to the inhibitory effects of FIH1 under normoxic conditions and that, perhaps as a result, both the NTAD and CTAD cooperate to promote renal carcinogenesis in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HIF2α is relatively resistant to FIH1-mediated inactivation compared to HIF1α (Bracken et al., 2006; Yan et al., 2007).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Yan et al., 2007
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 2×
“Most solid tumors contain hypoxic regions in which HIF is stabilized and active, as determined by the induction of HIF target genes that promote survival in a hypoxia environment (18).”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“786-O renal carcinoma cell subclones stably transfected with pRc-CMV-HA-VHL (WT7) ( 27 ) were grown in DMEM containing 10% fetal clone I (HyClone) containing 1 mg/ml G418 in a 37°C, 10% CO2 incubator.”
MethodEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 1×
“These genes include genes that control angiogenesis (such as vascular endothelial growth factor [VEGF]), energy metabolism (for example, the glucose transporter 1 [GLUT1] and carbonic anhydrase IX [CAIX]), erythropoiesis (such as erythropoietin [EPO]), and mitogenesis (for example, transforming growth factor and plate…”
BackgroundRegulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 1×
“HIF (hypoxia-inducible factor) is a master transcriptional regulator of hypoxia-inducible genes and is composed of the subunit HIF1, or one of its paralogs HIF2 or HIF3, and a HIF subunit, such as HIF1 (also called the aryl hydrocarbon receptor nuclear translocator [ARNT]) (12, 14, 17, 20, 50 , 53).”
BackgroundHIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 4×
“Mutation of the relevant hydroxylation sites renders these GAL4 fusions constitutively active and insensitive to oxygen (19, 36, 37 ).”
BackgroundInfluentialLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 8×
“Like the EglN prolyl hydroxylases, FIH1 is an Fe(II) and 2-oxoglutarate-dependent dioxygenase, and its activity can be blocked with competitive inhibitors of 2-oxoglutarate and with iron chelators (19, 36).”
BackgroundInfluentialDifferential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Tian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351 · cited 3×
“HIF2 , also known as EPAS1, HLF, HRF, or MOP2, shares 48% overall identity with HIF1 (12, 14, 20, 53).”
BackgroundExpression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001) · Nature Biotechnology · doi:10.1038/86730 · Cited by 1,298
Self-citationGao, X., Wu, G., Gu, X., Fu, L., & Mei, C. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000355743 · Cited by 1,035
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 3×
“HIF (hypoxia-inducible factor) is a master transcriptional regulator of hypoxia-inducible genes and is composed of the subunit HIF1, or one of its paralogs HIF2 or HIF3, and a HIF subunit, such as HIF1 (also called the aryl hydrocarbon receptor nuclear translocator [ARNT]) ( 12 , 14, 17, 20, 50, 53).”
BackgroundInfluentialRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Self-citationMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Self-citationA PCR primer bank for quantitative gene expression analysis
Wang, X. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng154 · Cited by 859
HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181341498 · Cited by 796
Gu, Y.-Z., Moran, S. M., Hogenesch, J. B., Wartman, L. D., & Bradfield, C. A. (1998) · Europe PMC (PubMed Central) · Cited by 769
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761 · cited 4×
“Recent studies suggest that HIF2 is more important for renal carcinogenesis than HIF1 (4, 33, 40, 41).”
BackgroundMethodInfluentialSelf-citationHewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y.-M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200273200 · Cited by 719
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationTransactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α
Jiang, B.-H., Zheng, J. Z., Leung, S. W., Roe, R., & Semenza, G. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19253 · Cited by 629
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611 · cited 7×
“pcDNA3.0-HA-HIF2 P405A/P531A/N847Q was made by site-directed mutagenesis of pcDNA3.0-HA-HIF2 P405A/P531A ( 32 ) with sense primer I (G ACTGTGAGGTGCAAGTGCCCGTGCTGG) using the QuikChange sitedirected mutagenesis kit (Stratagene).”
BackgroundMethodResultInfluentialSelf-citationEma, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1905 · Cited by 587
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
Self-citationTang, N., Wang, L., Esko, J., Giordano, F. J., Huang, Y., Gerber, H.-P., Ferrara, N., & Johnson, R. S. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.026 · Cited by 540
Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit
Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., & Ratcliffe, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11205 · Cited by 532
Hogenesch, J. B., Chan, W. K., Jackiw, V. H., Brown, R. C., Gu, Y.-Z., Pray-Grant, M., Perdew, G. H., & Bradfield, C. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8581 · Cited by 513
Suppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
Self-citationHIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480 · cited 1×
“In most but not all models, genetic disruption of HIF1 or its partner, ARNT1, leads to decreased tumor formation in vivo (44, 47, 52), as does blocking the interaction of HIF with the coactivator proteins p300/CBP (34, 35 ).”
BackgroundElvidge, G. P., Glenny, L., Appelhoff, R. J., Ratcliffe, P. J., Ragoussis, J., & Gleadle, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511408200 · Cited by 464 · cited 1×
“It is also increasingly clear that some genes are preferentially regulated by different HIF proteins (3, 10 , 21, 45).”
BackgroundStructural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α
Freedman, S. J., Sun, Z.-Y. J., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., & Eck, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082117899 · Cited by 455
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 432
Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response
Dames, S. A., Martinez-Yamout, M., De Guzman, R. N., Dyson, H. J., & Wright, P. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082121399 · Cited by 402
Elkins, J. M., Hewitson, K. S., McNeill, L. A., Seibel, J. F., Schlemminger, I., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200644200 · Cited by 391
Flamme, I., Fröhlich, T., von Reutern, M., Kappel, A., Damert, A., & Risau, W. (1997) · Mechanisms of Development · doi:10.1016/s0925-4773(97)00674-6 · Cited by 366
Carroll, V. A., & Ashcroft, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2519 · Cited by 352
Dayan, F., Roux, D., Brahimi-Horn, M. C., Pouyssegur, J., & Mazure, N. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4564 · Cited by 294
Ebert, B. L., & Bunn, H. F. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4089 · Cited by 282
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
O'Rourke, J. F., Tian, Y.-M., Ratcliffe, P. J., & Pugh, C. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2060 · Cited by 242 · cited 2×
“To pursue this further, we generated an HIF2 variant in which the residues that are essential for the NTAD function were eliminated by an in-frame deletion (Fig. 1A, dN) (11, 42 ).”
MethodFailure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235 · cited 1×
“The latter finding, coupled with the fact that HIF1, but not HIF2 ,i s still subject to proteasomal degradation in pVHL-defective cells (25, 31 ), might explain why HIF2 plays a more prominent oncogenic role in VHL/ renal carcinoma cells than does HIF1.”
BackgroundBracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222 · cited 1×
“This observation is consistent with a recent study that showed that HIF2 is a poor FIH1 substrate in vitro relative to HIF1, in part because of differences in residues immediately following their respective Asn hydroxylation sites ( 1 ).”
ResultDann, C. E., Bruick, R. K., & Deisenhofer, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202614999 · Cited by 200
Stolze, I. P., Tian, Y.-M., Appelhoff, R. J., Turley, H., Wykoff, C. C., Gleadle, J. M., & Ratcliffe, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406713200 · Cited by 156
Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., & Caro, J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.9.2984-2992.2002 · Cited by 143 · cited 1×
“N-terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD) (11, 29, 42, 43, 46, 48 ).”
Rankin, E. B., Higgins, D. F., Walisser, J. A., Johnson, R. S., Bradfield, C. A., & Haase, V. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3163-3172.2005 · Cited by 139
Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., & Ryu, S. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210385200 · Cited by 121
Covello, K. L., Simon, M. C., & Keith, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3246 · Cited by 121
Functional Analysis of Hypoxia-inducible Factor-1α-mediated Transactivation
Ruas, J. L., Poellinger, L., & Pereira, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205051200 · Cited by 112
Identification of Alternative Spliced Variants of Human Hypoxia-inducible Factor-1α
Gothié, E., Richard, D. E., Berra, E., Pagès, G., & Pouysségur, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6922 · Cited by 100
Isaacs, J. S., Jung, Y.-J., & Neckers, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313342200 · Cited by 76
Dann (2002) · Medical Entomology and Zoology · Cited by 58
Cited by
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
“Moreover, HIF2a is relatively resistant to FIH1-mediated inactivation compared to HIF1a (Bracken et al., 2006; Yan et al., 2007).”
BackgroundSelf-citationHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
Kaelin Jr, W. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2502 · Cited by 726
“HIF2α is less sensitive than HIF1α to inhibition by FIH1, which should be active in oxygenated VHL-defective cell”
BackgroundSelf-citationZhou, W., Choi, M., Margineantu, D., Margaretha, L., Hesson, J., Cavanaugh, C., Blau, C. A., Horwitz, M. S., Hockenbery, D., Ware, C., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.71 · Cited by 555
“To obtain constitutively stable expression HIF1 a protein, non-degrad-able HIF1 a overexpressing plasmid (Addgene plasmid 19005) was used, in which two of the proline sites of HIF1 a cDNAwere changed to alanine as described previously (Yan et al , 2007).”
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., & Holland, E. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.005 · Cited by 540
“Oxygen-insensitive mutants of HIF1A and HIF2A (Yan et al., 2007) were obtained from Addgene (#18955 and #18956, respectively).”
BackgroundMethod
Metadata
- Authors
- Yan, Q., Bartz, S., Mao, M., Li, L., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Rosetta Inpharmatics, LLC.
- Corresponding author
- Kaelin, William G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-03-01
- Volume
- 27
- Issue
- 6
- Pages
- 2092-2102
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1820491
- OpenAlex
- W2161071327
- Cited by
- 193
- References
- 58
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 10 · 2020: 14 · 2019: 19 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 7 · 2014: 11 · 2013: 14 · 2012: 9
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Dana-Farber/Harvard Cancer Center
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- HIF-2α, hypoxia-inducible factor, N-terminal transactivation domain, C-terminal transactivation domain, renal carcinogenesis, kidney cancer, VHL, prolyl hydroxylation, transcriptional activation, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Amino Acid Sequence, Animals, Cell Line, Cell Transformation, Neoplastic, Humans, Kidney Neoplasms, Mice, Nude, Molecular Sequence Data, Mutation, Transcriptional Activation, Sequence Alignment, Conserved Sequence, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Rats, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.